Showing results (381-390 of 561) with videos related to
Sort By:
Pageof 57
Expert Review of Anticancer Therapy|April 27, 2013
Current opinion on optimal treatment for colorectal cancerTimothy J Price, Eva Segelov, Matthew Burge, et al.Histopathology|February 22, 2018
Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trialNasser Davarzani, Gordon G A Hutchins, Nicholas P West, et al.Journal of Interventional Cardiology|December 31, 2013
Do outcomes from transcatheter aortic valve implantation vary according to access route and valve type? The UK TAVI RegistryDaniel J Blackman, Paul D Baxter, Chris P Gale, et al.Rare Tumors|January 26, 2023
PARP inhibition utilized in combination therapy with Olaparib-Temozolomide to achieve disease stabilization in a rare case of BRCA1-mutant, metastatic myxopapillary ependymomaPreethika Mahalingam, Sam Smith, Juanita Lopez, et al.Journal of the National Cancer Institute|June 25, 2014
TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trialFrancesco Sclafani, David Gonzalez, David Cunningham, et al.World Journal of Surgery|March 10, 2022
Impact of the COVID-19 Pandemic on Pediatric Surgical Volume in Four Low- and Middle-Income Country Hospitals: Insights from an Interrupted Time Series AnalysisPaul Park, Ruth Laverde, Greg Klazura, et al.British Journal of Haematology|March 6, 2010
Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHLDavid C Linch, Lynny Yung, Paul Smith, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2008
Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphomaRobert Marcus, Kevin Imrie, Philippe Solal-Celigny, et al.British Journal of Haematology|March 22, 2003
Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphomaIan Chau, Mark Harries, David Cunningham, et al.Cancer Immunology, Immunotherapy : CII|December 3, 2013
The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancerNicola E Annels, Victoria E Shaw, Rachel F Gabitass, et al.Pageof 57